Kingwood, TX, United States of America

Garth L Nicolson

This inventor holds 6 USPTO granted patents. Top assignee: The University of Texas System. Active years: 1989-1995.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Garth L Nicolson. Retrieved from https://idiyas.com/inventor/garth-l-nicolson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 2.6

ph-index = 5

Forward Citations = 84(Granted Patents)


Location History:

  • Kingswood, TX (US) (1994)
  • Kingwood, TX (US) (1989 - 1995)

Company Filing History:


Years Active: 1989-1995

Loading Chart...
6 patents (USPTO):Explore Patents

Title: Garth L Nicolson: Innovator in Tumor Cell Growth Inhibition

Introduction

Garth L Nicolson is a prominent inventor based in Kingwood, TX (US). He has made significant contributions to the field of cancer research, particularly in the development of tumor cell growth inhibitors. With a total of 6 patents to his name, Nicolson's work has the potential to impact cancer treatment methodologies.

Latest Patents

One of Nicolson's latest patents is focused on a liver-derived tumor cell growth inhibitor. This factor has been purified from rat liver homogenate and exhibits preferential growth inhibitory effects on non-liver metastasizing tumor cells. The purification process involves several sophisticated techniques, including heat treatment, ammonium sulfate precipitation, and various chromatography methods. The growth inhibitor has an apparent molecular weight of 38 kD to 40 kD and a pI of 9.1. Notably, it is not affected by reducing agents and shows no biological TGF-b activity. This inhibitor demonstrates a lesser antiproliferative effect on liver metastasizing cells compared to their non-liver metastasizing counterparts in two tumor systems: the murine RAW117 large cell lymphoma and the human A375 melanoma.

Another significant patent involves a solid-phase substrate containing modified heparin. This substrate yields soluble labeled products upon hydrolysis by a glycosaminoglycan endoglycosidase. The invention includes methods for producing this substrate, which comprises glycosaminoglycan bearing labeled substances bound to amino groups. The labeled glycosaminoglycan substrate is reductively aminated at its reducing terminal end to produce an amine-terminus, which is then coupled to an amino-reactive solid matrix.

Career Highlights

Nicolson's career has been marked by his dedication to advancing cancer research. His innovative approaches to tumor cell growth inhibition have garnered attention in the scientific community. He is affiliated with the University of Texas System, where he continues to contribute to research and development in this critical area.

Collaborations

Throughout his career, Nicolson has collaborated with notable colleagues, including Tatsuro Irimura and Motowo Nakajima. These partnerships have further enriched his research endeavors and expanded the impact of his inventions.

Conclusion

Garth L Nicolson's work in the field of tumor cell growth inhibition exemplifies the importance

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…